Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study.

E Pauliat; M Onken; C Weber-Schoendorfer; V Rousson; MC Addor; D Baud; M Theaudin; O Diav-Citrin; J Cottin; M. Antonieta Agusti Escasany; V Rollason; YC Kaplan; D Kennedy; M Kadioglu; LE Rothuizen; F Livio; T Buclin; A Panchaud; U Winterfeld

doi:10.1177/1352458520929628

Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study.

E Pauliat^*, M Onken, C Weber-Schoendorfer, V Rousson, MC Addor, D Baud , M Theaudin, O Diav-Citrin, J Cottin, M. Antonieta Agusti Escasany, V Rollason, YC Kaplan, D Kennedy, M Kadioglu, LE Rothuizen , F Livio, T Buclin, A Panchaud, U Winterfeld^*

^*Corresponding author for this work

Department of Pharmacology, Therapeutics and Toxicology

Research output: Contribution to journal › Article › Research › peer-review

17 Citations (Scopus)

Abstract

This prospective multicentre cohort study investigated pregnancy outcomes after fingolimod use for multiple sclerosis during pregnancy. Pregnancy outcomes of 63 fingolimod and 62 interferon-β-exposed pregnancies were compared. Rates of major congenital anomalies (MCA) were 4.8% (2/42) in the fingolimod group versus 2.3% (1/44) in the interferon-β group (odds ratio, 2.2; 95% confidence interval, 0.2–24.6). The adjusted hazard ratio for spontaneous abortion in fingolimod versus interferon-β-exposed pregnancies was 0.6 (95% confidence interval, 0.2–1.8). Further studies are needed to definitely rule out a moderately increased MCA risk after fingolimod exposure during pregnancy.

Original language	English
Pages (from-to)	475-478
Number of pages	4
Journal	Multiple Sclerosis Journal
Volume	27
Issue number	3
DOIs	https://doi.org/10.1177/1352458520929628
Publication status	Published - Mar 2021

Access to Document

10.1177/1352458520929628

Cite this

Pauliat, E., Onken, M., Weber-Schoendorfer, C., Rousson, V., Addor, MC., Baud , D., Theaudin, M., Diav-Citrin, O., Cottin, J., Agusti Escasany, M. A., Rollason, V., Kaplan, YC., Kennedy, D., Kadioglu, M., Rothuizen , LE., Livio, F., Buclin, T., Panchaud, A., & Winterfeld, U. (2021). Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study. Multiple Sclerosis Journal, 27(3), 475-478. https://doi.org/10.1177/1352458520929628

@article{80430cd76dd84d5ea8e21faf6fb34fca,

title = "Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study.",

abstract = "This prospective multicentre cohort study investigated pregnancy outcomes after fingolimod use for multiple sclerosis during pregnancy. Pregnancy outcomes of 63 fingolimod and 62 interferon-β-exposed pregnancies were compared. Rates of major congenital anomalies (MCA) were 4.8% (2/42) in the fingolimod group versus 2.3% (1/44) in the interferon-β group (odds ratio, 2.2; 95% confidence interval, 0.2–24.6). The adjusted hazard ratio for spontaneous abortion in fingolimod versus interferon-β-exposed pregnancies was 0.6 (95% confidence interval, 0.2–1.8). Further studies are needed to definitely rule out a moderately increased MCA risk after fingolimod exposure during pregnancy.",

author = "E Pauliat and M Onken and C Weber-Schoendorfer and V Rousson and MC Addor and D Baud and M Theaudin and O Diav-Citrin and J Cottin and {Agusti Escasany}, {M. Antonieta} and V Rollason and YC Kaplan and D Kennedy and M Kadioglu and LE Rothuizen and F Livio and T Buclin and A Panchaud and U Winterfeld",

year = "2021",

month = mar,

doi = "10.1177/1352458520929628",

language = "English",

volume = "27",

pages = "475--478",

journal = "Multiple Sclerosis Journal",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "3",

}

Pauliat, E, Onken, M, Weber-Schoendorfer, C, Rousson, V, Addor, MC, Baud , D, Theaudin, M, Diav-Citrin, O, Cottin, J, Agusti Escasany, MA, Rollason, V, Kaplan, YC, Kennedy, D, Kadioglu, M, Rothuizen , LE, Livio, F, Buclin, T, Panchaud, A & Winterfeld, U 2021, 'Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study.', Multiple Sclerosis Journal, vol. 27, no. 3, pp. 475-478. https://doi.org/10.1177/1352458520929628

TY - JOUR

T1 - Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study.

AU - Pauliat, E

AU - Onken, M

AU - Weber-Schoendorfer, C

AU - Rousson, V

AU - Addor, MC

AU - Baud , D

AU - Theaudin, M

AU - Diav-Citrin, O

AU - Cottin, J

AU - Agusti Escasany, M. Antonieta

AU - Rollason, V

AU - Kaplan, YC

AU - Kennedy, D

AU - Kadioglu, M

AU - Rothuizen , LE

AU - Livio, F

AU - Buclin, T

AU - Panchaud, A

AU - Winterfeld, U

PY - 2021/3

Y1 - 2021/3

N2 - This prospective multicentre cohort study investigated pregnancy outcomes after fingolimod use for multiple sclerosis during pregnancy. Pregnancy outcomes of 63 fingolimod and 62 interferon-β-exposed pregnancies were compared. Rates of major congenital anomalies (MCA) were 4.8% (2/42) in the fingolimod group versus 2.3% (1/44) in the interferon-β group (odds ratio, 2.2; 95% confidence interval, 0.2–24.6). The adjusted hazard ratio for spontaneous abortion in fingolimod versus interferon-β-exposed pregnancies was 0.6 (95% confidence interval, 0.2–1.8). Further studies are needed to definitely rule out a moderately increased MCA risk after fingolimod exposure during pregnancy.

AB - This prospective multicentre cohort study investigated pregnancy outcomes after fingolimod use for multiple sclerosis during pregnancy. Pregnancy outcomes of 63 fingolimod and 62 interferon-β-exposed pregnancies were compared. Rates of major congenital anomalies (MCA) were 4.8% (2/42) in the fingolimod group versus 2.3% (1/44) in the interferon-β group (odds ratio, 2.2; 95% confidence interval, 0.2–24.6). The adjusted hazard ratio for spontaneous abortion in fingolimod versus interferon-β-exposed pregnancies was 0.6 (95% confidence interval, 0.2–1.8). Further studies are needed to definitely rule out a moderately increased MCA risk after fingolimod exposure during pregnancy.

U2 - 10.1177/1352458520929628

DO - 10.1177/1352458520929628

M3 - Article

SN - 1352-4585

VL - 27

SP - 475

EP - 478

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

IS - 3

ER -

Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study.

Abstract

Access to Document

Fingerprint

Cite this